Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 5.9 %

PULM stock opened at $7.20 on Friday. The firm has a 50 day moving average of $5.20 and a 200-day moving average of $3.17. The company has a market cap of $26.29 million, a price-to-earnings ratio of -2.73 and a beta of 1.52. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $8.44.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.